文献速递肾小球疾病

抗髓过氧化物酶血管炎中髓系Mcl1表达是必需的,但抑制髓过氧化物酶无保护作用

Myeloid expression of the anti-apoptotic protein Mcl1 is required in anti-myeloperoxidase vasculitis but myeloperoxidase inhibition is not protective.
PubMed 文献 · Kidney Int · 2022-09-14

在抗髓过氧化物酶抗体诱导的小鼠抗中性粒细胞胞质抗体血管炎模型中,髓系特异性敲除抗凋亡蛋白Mcl1的小鼠较对照组肾小球新月体、中性粒细胞和巨噬细胞减少,血清肌酐降低,白蛋白尿减轻;而髓过氧化物酶抑制剂AZD5904和AZM198对疾病组织学或生化指标及白蛋白尿均无影响。

要点

  • 髓系特异性Mcl1缺失可减轻小鼠抗髓过氧化物酶血管炎肾小球损伤。
  • AZD5904抑制髓过氧化物酶对组织学、生化指标及白蛋白尿均无影响。
  • AZM198同样无效应证据,但两种抑制剂体外均抑制人中性粒细胞胞外诱捕网形成。

核心结论

  • 髓系特异性Mcl1在该抗髓过氧化物酶血管炎模型中为疾病发生所必需。
  • 抑制髓过氧化物酶在该模型中无保护作用。

研究设计与样本

  • 小鼠抗中性粒细胞胞质抗体血管炎模型,由抗髓过氧化物酶抗体诱导。
  • 比较髓系特异性Mcl1敲除小鼠与对照小鼠。
  • 评估髓过氧化物酶抑制剂AZD5904和AZM198的效应。

主要发现

  • Mcl1敲除小鼠较对照肾小球新月体、中性粒细胞和巨噬细胞减少,血清肌酐降低,白蛋白尿减轻。
  • Mcl1敲除小鼠基线及诱导后第6天循环中性粒细胞少于对照,第6天循环单核细胞也减少。
  • AZD5904对疾病组织学或生化参数无影响,诱导后第1、2、5、7天白蛋白尿无减少。
  • 去除粒细胞集落刺激因子诱导疾病后上述结果持续存在。
  • AZM198同样无效应证据,但AZD5904和AZM198体外均抑制人中性粒细胞胞外诱捕网形成。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibodies to neutrophil and monocyte myeloperoxidase and proteinase 3 are a feature of anti-neutrophil cytoplasmic antibody vasculitis, a disease with significant morbidity for which new treatments are needed. Mice with a myeloid-specific deletion of the anti-apoptotic protein Mcl1 have reduced numbers of circulating neutrophils. Here, we assessed if myeloid-specific Mcl1 was required in murine anti-myeloperoxidase vasculitis and whether inhibition of myeloperoxidase was protective. In a murine model of anti-neutrophil cytoplasmic antibody vasculitis, induced by anti-myeloperoxidase antibody, mice with a myeloid-specific deletion of Mcl1 were protected from disease. They had fewer crescents, neutrophils, and macrophages in the glomeruli, lower serum creatinine levels and reduced albuminuria compared with controls. At baseline and day six after disease induction they had fewer circulating neutrophils than controls. At day six there were also fewer circulating monocytes. Myeloperoxidase inhibition with AZD5904 had no effect on histological or biochemical parameters of disease, and there was also no reduction in albuminuria at day one, two, five or seven after disease induction. These findings persisted when disease was induced without granulocyte-colony stimulating factor, which increases disease severity. A second myeloperoxidase inhibitor, AZM198, also showed no evidence of an effect, although both AZD5904 and AZM198 inhibited human neutrophil extracellular trap formation in vitro. Thus, our results show that while myeloid-specific Mcl1 is required in this model of anti-myeloperoxidase vasculitis, myeloperoxidase inhibition is not protective.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Florez-Barros F, Bearder S, Kull B, et al. Myeloid expression of the anti-apoptotic protein Mcl1 is required in anti-myeloperoxidase vasculitis but myeloperoxidase inhibition is not protective. Kidney Int. 2022. PMID: 36154801. doi:10.1016/j.kint.2022.08.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。